NCT05625529Recruiting
ExoLuminate Study for Early Detection of Pancreatic Cancer
Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients
Source: ClinicalTrials.gov · Last updated 28 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis. The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 15 Nov 2022
- Start date
- 19 Dec 2022
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- Biological Dynamics
- Diseases
- Pancreatic cancer
- NCT number
- NCT05625529
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 19 Dec 2022 to the primary completion date, 1 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior organ transplant or bone marrow transplant.
Other illness
- Active cancer (other than pancreatic cancer) and/or undergoing treatment for an active cancer diagnosis (except for skin malignancies).
- History of fainting or other adverse effects when blood is drawn.
- Any condition that, in the opinion of the investigator, should preclude enrollment.
Age
- \< 18 years old.
Other
- Pregnancy.
Who the study is looking for
- ≥18 years old.
- Meeting criteria for one of the study cohorts.
- Capable of giving informed consent.
- Able to provide a blood sample.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Biological Dynamics Coordinator of this site? Confirm its status | San Diego | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.